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Educational Case




Kaitlyn C. Dykes, MD1 and Alexis R. Peedin, MD1
The following fictional case is intended as a learning tool within the Pathology Competencies for Medical Education (PCME),
a set of national standards for teaching pathology. These are divided into three basic competencies: Disease Mechanisms and
Processes, Organ System Pathology, and Diagnostic Medicine and Therapeutic Pathology. For additional information, and
a full list of learning objectives for all three competencies, see http://journals.sagepub.com/doi/10.1177/2374289517715040.1
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Primary Learning Objective
Objective TM1.3: Infectious Risk. Discuss infectious disease
risks of transfusion.
Competency 3: Diagnostic Medicine and Therapeutic
Pathology; Topic TM: Transfusion Medicine; Learning Goal
1: Concepts of Blood transfusion.
Secondary Learning Objective
Objective M6.4: Malaria and Babesiosis. Contrast Plasmodium
falciparum with other malaria species and babesiosis on a
blood smear and explain the role of thick and thin smears in
the diagnosis and management of malaria.
Competency 3: Diagnostic Medicine and Therapeutic
Pathology; Topic M: Microbiology; Learning Goal 6:
Parasitology.
Patient Presentation
A 76-year-old female underwent liver transplant due to non-
alcoholic steatohepatitis cirrhosis. Her hospitalization was
prolonged. Posttransplant she received 50 units of packed
red blood cells (PRBCs), 1 unit of platelets, and 2 units of
plasma (Figure 1). On hospital day 21, she had a positive
direct antibody test immunoglobulin G; she was found to
have developed new anti-RBC surface antigen alloantibody:
anti-K.
Diagnostic Findings, Part 1
Three months into her hospitalization, she developed recurrent,
noncyclic fevers (up to 39 C). Fevers persisted despite
broad-spectrum antibiotic treatment. Physical examination was
pertinent for new altered mental status.
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Questions/Discussion Points, Part 1
Formulate a Differential Diagnosis Based on This
Presentation and Propose a Plan for Further Workup.
Given this presentation, the differential diagnosis included
infection and transplant rejection. Infection was high on the
differential because infection can cause fevers and altered men-
tal status. Further, the patient was immunocompromised due to
immunosuppression necessary after transplant. This put her at
increased risk of bacterial, fungal, and viral infections. Acute
transplant rejection was also high on the differential because it
occurs weeks to months after transplant and can present with
fever and flu-like symptoms.2
Diagnostic Findings, Part 2
An extensive infectious disease workup was negative, includ-
ing blood and spinal fluid cultures, acid-fast stains of cerebral
spinal fluid, Cryptococcus antigen testing and cytomegalovirus
(CMV) polymerase chain reaction (PCR). A liver biopsy was
performed and displayed in Figure 2.
Figure 1. The patient received 53 blood transfusions: 50 units of PRBC, 1 unit of platelets, and 2 units of plasma. A total of 35 units of PRBCs,
1 unit of platelets, and 2 units of plasma were transfused before she became febrile. PRBC indicates packed red blood cells.
Figure 2. Gross microscopy of liver biopsy on hospital day 105 showed nonspecific cholestasis and no evidence of acute rejection or necrosis.
Trichrome stain showed no fibrosis, confirmed by the reticulin stain. Kupffer cell hemosiderosis is present.
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Questions/Discussion Points, Part 2
What Are the Findings of Acute Rejection on Liver Biopsy?
On biopsy, patients with acute rejection have bile duct
lymphocytic infiltrate and necrosis due to infiltration of
T-cells attacking the bile duct of the transplanted liver.2 The
patient’s biopsy demonstrated normal liver histology, including
lobules and bile ducts with no lymphocytic infiltration, necro-
sis, or significant cholestasis (Figure 2). The biopsy was neg-
ative for acute rejection.
Diagnostic Findings, Part 3
Subsequently, the patient was found to be pancytopenic with
reticulocytosis (15.3%; normal 0.5%-1.5%). She developed
up-trending lactate dehydrogenase (LDH), direct and indirect
bilirubin, and had undetectable haptoglobin (Figure 3). Her
liver function progressively worsened, with liver function
enzyme levels in the mid-100s.
On hospital day 107, the patient experienced worsening
mental status, hypotension (79/40 mm Hg), and an acute hemo-
globin drop from 8.2 to 6.6 g/dL without an obvious source of
bleeding, requiring 1 unit of PRBCs and with subsequent inap-
propriate posttransfusion hemoglobin response. See Table 1 for
a complete set of labs.
Questions/Discussion Points, Part 3
Given This Presentation and Constellation of Laboratory
Findings, Can You Narrow Your Differential and Propose
Possible Underlying Etiologies?
Anemia in the setting of hyperproliferative reticulocytosis
(15.3%; normal 0.5%-1.5%), up-trending LDH, indirect
bilirubin, and an undetectable haptoglobin, is consistent with
a diagnosis of hemolytic anemia, the lysis of red blood cells.3
Even more specifically, the elevated indirect bilirubin and low
haptoglobin indicated intravascular hemolysis.3
What Are Causes of Hemolytic Anemia in Patients Who
Have Received Transfusions?
Hemolytic anemia in recently transfused patients has a wide
differential including acute hemolytic transfusion reactions
Figure 3. Lactate dehydrogenase (LDH) and total bilirubin levels throughout the patient’s hospitalization. There is an initial LDH spike at the
time of transplant and a second elevation that temporally correlated with initiation of fevers, clinical decomposition, and additional lab
aberrancies.
Table 1. Laboratory Values, Day 107.a
Chem 7 Reference range
Sodium (mmol/L) 139 136-144
Potassium (mmol/L) 4.2 3.6-5.1
Chloride (mmol/L) 103 101-111
HCO3 (mmol/L) 19 (L) 22-32
Blood urea nitrogen (mg/dL) 24 (H) 74-106
Creatinine (mg/dL) 2.22 (H) 0.6-1.3
Glucose (mg/dL) 140 (H) 74-106
Complete blood count
White blood cell (K/uL) 20 (H) 4.8-10.8
Hemoglobin 6.6 (L) 12.6-17.4
Hematocrit 19.8 (L) 37.0-51.0
Platelets 90 (L) 130-400
Additional labs
AST (IU/L) 161 (H) 5-50
ALT (IU/L) 153 (H) 17-63
Total bilirubin (mg/dL) 14.8 (H) 0.3-1.2
Direct bilirubin (mg/dL) 1.8 (H) <1
Alk Phos (IU/L) 115 (H) 32-91
Lactate dehydrogenase (IU/L) 1156 (H) 150-250
aReference range varies by institution. Bolded values highlight laboratory
abnormalities.
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(AHTRs), delayed hemolytic transfusion reactions (DHTRs),
and hemolytic anemia secondary to transfusion-transmitted
infection (TTI).3-5 Acute hemolytic transfusion reactions can
range from mild to life-threatening and occur within 24 hours
of transfusion.3 Acute hemolytic transfusion reactions are
caused by the activation of the complement cascade in the
presence of antigen: antibody complexes, leading to intravas-
cular hemolysis.3 Transfusion of ABO-incompatible PRBCs
causes most AHTRs, estimated to occur in 1:38 000 to 1:100
000 transfusions.3 An AHTR was unlikely in this case given the
chronicity of hemolysis, and that all PRBC units were con-
firmed to be ABO compatible.
Delayed hemolytic transfusion reactions occur 3 to 10 days
following transfusion in patients who have previously been all
immunized to non-ABO RBC antigens during previous trans-
fusions or pregnancy.4 Patients found to have alloantibodies
should be transfused with PRBCs that are antigen-negative.4
Titers of alloantibodies may wane over time, causing some
patients to have negative antibody screens.4 In these patients,
the blood bank may not be aware of the presence of the
alloantibody and could issue antigen-positive PRBC units. This
reexposure would result in a rapid rise in antibody titer, leading
to a DHTR.4 Delayed hemolytic transfusion reactions cause
predominantly extravascular hemolysis, with milder clinical
signs and symptoms than AHTRs.3,4 In this case, a DHTR was
on the differential because of the newly discovered alloanti-
body and clinical timeline but refuted by the presence of severe
intravascular hemolysis. Additionally, the PRBC units were all
negative for the Kell antigen against which she was all
immunized.
Progressive hemolytic anemia in an immunosuppressed,
febrile patient was highly suspicious for an infectious etiology.
Because she had received so many blood transfusions during
her hospitalization, a TTI was considered. Babesiosis and
malaria are 2 not able protozoan TTIs that can cause hemolytic
anemia.5
What Are the Infectious Disease Risks of Transfusion?
Viruses, bacteria, protozoa, and prions can all cause TTIs.5
Pathogens that cause TTI must be blood-borne, survive prod-
uct processing, be parentally infectious, and cause morbidity
in a susceptible recipient pool.5 Transfusion-transmitted
viruses include the hepatitis viruses, HIV, CMV, parvovirus,
and EBV. Hepatitis A and C are each transmitted in less than 1
in 1 million red cell transfusions, while the rate of HIV trans-
mission is 1 in 1.5 to 2 million transfusions.5 Bacterial TTIs
are due to organisms from donor blood, skin, or environmen-
tal contamination. They are estimated to occur in 0.2 per 1
million transfusions.5 Babesiosis and malaria are infections
cause by protozoa that vary widely in incidence based on
geographic location.5 Incidence of babesiosis ranges from 1/
604 to 1/100 000 infections per RBC unit transfused.6
Transfusion-transmitted malaria is rare in the United States,
occurring an estimated 0 to 0.18 cases per million units
transfused or less.7 Creutzfeldt-Jakob disease can be
transfusion transmitted and has been observed in a limited
number of cases, albeit exceedingly rarely.5 Risk reduction
may be achieved through careful donor recruitment,
questioning and testing, along with aseptic phlebotomy
technique.5 Despite a variety of test methodologies used for
many TTIs, there remains a subset of TTIs for which there is
no universal donor testing in the United States (Table 2).8
Both babesiosis and malaria fall into this category.8
Diagnostic Findings, Part 4
On hospital day 108, a blood smear was obtained, depicted in
Figure 4.




 Hepatitis B virus
 Hepatitis C virus
 West Nile Virus
 Zika virus
Serological testing
 HIV-1 and -2
 Hepatitis B virus
 Hepatitis C virus
 Human T-Lymphotropic virus types I and II





 Variant Creutzfeldt-Jakob disease
aData as of 2018 FDA requirements.8
Figure 4. Thin blood smear obtained on day 108 with many
intra- and extraerythrocytic pleomorphic and pyriform ring-
shaped organisms, >10% parasitemia. Consistent with Babesia
morphology.9,10
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Questions/Discussion Points, Part 4
Which Pathogens Have Ring Forms on Blood Smear and
How Do You Differentiate Them?
Blood smear revealed intra- and extraerythrocytic pleomorphic
and pyriform ring-shaped organisms. The parasitemia estimate
was >10%, a critically high level. Babesia subspecies and Plas-
modium subspecies have microscopic ring-shaped morpholo-
gies on blood smear, cause similar clinical presentations, and
infect erythrocytes selectively.9-11
Babesia are characterized by small, pleomorphic intra-, and
extraerythrocytic ring forms (Figure 4).9,10 Maltese cross tet-
rads are pathognomonic for Babesia, but this form is rarely
seen in human hosts.10,12 Plasmodium, the cause of malaria,
is located only within erythrocytes and is characterized by ring
forms, schizonts, and gametocytes (Figure 5).9,10 Plasmodium
species can be further differentiated by the size of infected
erythrocytes, parasitemia level, number of merozoites, and
gametocyte type.9 For example, the most pathogenic species,
P falciparum, is associated with infection of erythrocytes in all
stages of maturation and high parasitemia levels.9
Microscopy-based identification has limitations, despite
being the mainstay of diagnosis for these parasites. Thick blood
smears, a drop of blood on glass, are used to establish the presence
of parasites. Thin blood smears, a drop of blood spread across a
large portion of the slide, are used to calculate percent parasitemia
and examine morphology.11 Only *60% of Babesia infections
are detected on blood smear.12 Microscopy-based diagnosis is
challenging because of the small parasite size, sparse parasitemia
in the majority of infections, and low index of suspicion.12 In this
case, the diagnosis was missed on several blood smears that were
found to have parasitemia on retrospective review. Once recog-
nized, smears from this patient clearly demonstrated morphology
consistent with Babesia. This illustrates the difficulty of making
the diagnosis from blood smears alone without prior suspicion of
infection.
What Other Tests Are Used to Diagnose Babesiosis?
Babesiosis can be diagnosed by detecting Babesia DNA in
serum with nucleic acid testing (NAT), which is more sensitive
than thick prep blood smears.13 Additionally, serology testing
detects antibodies in serum to Babesia and indicates current or
past infection.14
Describe How Multiple Disciplines Need to Work
Collaboratively to Care for a Complex Patient Such
as This Patient?
Early diagnosis and treatment of babesiosis often requires
efforts from across the diagnostic laboratory and clinical spe-
cialties. This multidisciplinary case required involvement of
the microbiology laboratory, hematopathology, gross pathol-
ogy, and transfusion medicine. Additionally, it required con-
sultation by infectious diseases, hematology, hepatology
transplant surgery, and critical care physicians. Timely
Figure 5. Thin blood smears of Plasmodium falciparum and Plasmodium ovale compared to Babesia subspecies Images all taken at 100. Both
Babesia subspecies and Plasmodium subspecies form ring forms.9,10 Babesia ring forms are intracellular and extracellular, with characteristic ring
morphology (arrows).9 Plasmodium falciparum ring forms are located only within erythrocytes and are characterized by “headphone”
morphology (arrow head).9 Additionally, maturational forms of Plasmodium are often present and can be used to differentiate from Babesia,
such as shown by the Plasmodium ovale schizont.9,10 Malaria blood smear images were reproduced with permission from Dr Ashley Vogel, a
hematopathology fellow at Thomas Jefferson University Hospital.
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communication between disciplines allowed life-saving diag-
nosis and treatment for this patient.
Diagnostic Findings, Part 5
Subsequent Babesia microti NAT was positive, and malaria
antigen screen was negative. Given the patient’s severe clinical
decomposition and parasite burden, she underwent emergent
red blood cell exchange transfusion. After exchange transfu-
sion, parasitemia declined from >10% to 3.22% (Figure 6). The
patient was started on atovaquone and azithromycin.
She improved clinically and parasitemia became undetectable.
The patient completed 6 weeks of antimicrobials, including
2 weeks after the first negative smear. A follow-up smear
3 months later remained negative for parasites.
Questions/Discussion Points, Part 5
What Is Babesiosis?
Babesiosis is an infectious disease caused by Babesia, an intraer-
ythrocytic protozoan.10,15 Babesia species are endemic to the
Northeast and upper Midwest regions of the United States.10,16
Humans most often acquire infection from B microti when spor-
ozoites are introduced through a bite from an infected Ixodes sca-
pularis tick, but infection may also be transmitted via blood
transfusion, organ transplantation, and transplacentally.10,15 Spor-
ozoites enter human erythrocytes where they undergo asexual
reproduction and cause erythrocyte lyses.10 Sporozoites include
ring-shaped trophozoites and Maltese-cross shaped merozoites.9,10
Infection can be asymptomatic but often causes noncyclic
fevers, chills, sweats, headache, body aches, loss of appetite,
nausea or fatigue, dark urine, and jaundice.10 Symptomatic
infection is termed babesiosis.15 Babesiosis can be severe, with
complications including profound hypotension, hemolytic ane-
mia, thrombocytopenia, disseminated intravascular coagula-
tion, multi-organ failure, and death.10,13,15 Individuals with
weakened immune systems, other serious health conditions,
and the elderly have a particularly high risk of severe disease.10
How Do the Life Cycles and Presentation of Babesiosis
and Malaria Compare and Contrast?
The life cycles of Babesia subspecies and Plasmodium subspe-
cies are similar in that they both are transmitted by vectors,
have immature forms, infect red blood cells, form ring forms,
and ultimately cause hemolysis leading to similarities in clin-
ical presentation (Table 3).9-11,15-17
Specifically in malaria, infected Anopheles mosquitos trans-
mit malaria sporozoites into the blood stream.9 Sporozoites
then infect hepatocytes, where they grow and multiply into
schizonts.9 Eventually, the liver cells rupture and the parasite
enters the blood stream, where it infects RBCs. In RBCs, the
parasite forms trophozoites that mature into schizonts and
gametocytes.9 These forms also rupture RBCs, often cyclical
pattern, leading to symptomatic malaria.9 Gametocytes can be
transmitted from an infected host to a new host via the Ano-
pheles mosquito or via blood transfusion from an infected
donor.9
Like babesiosis, malaria can be characterized by symp-
toms of fever, chills, sweats, headache, body aches, loss of
appetite, nausea, fatigue, dark urine and jaundice.5,9 Malaria
fevers, depending on the subspecies, can be cyclical or ran-
dom.5 Meanwhile in babesiosis fevers are non-cyclical.9 The
timing of fever depends on the Plasmodium subspecies.
There are 5 Plasmodium subspecies, each with a slightly
different fever pattern related to differences in life cycle
timing.5 P. falciparum causes random fevers, while P.
knowlesi causes daily fevers.9 Plasmodium vivax and Plas-
modium ovale cause fevers every second day but can sur-
vive dormant for years in the liver.9 Plasmodium malariae
causes fever every third day.9
How Is Babesia Transmitted?
Babesiosis is considered an emerging infectious disease. For
example, in New York, more than 4600 cases of babesiosis
have been reported, since 1986 with 3500 of those reported
between 2006 and 2015.18 The increased incidence may be
partially attributable to increased awareness of the disease but
is also due to increasing deer and tick populations along with
Figure 6. Percent parasitemia calculated from thin blood smears, obtained on the day of diagnosis (108), until 2 negative smears on days 122 and
124. RBC exchange transfusion occurred on day 109 and a subsequent smear demonstrated a dramatic parasitemia decline to 3.22%.
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increased human habitat in endemic areas.13,18 Seroprevalence
in endemic areas ranges from 0.5% to 1.6%, indicating a high
rate of asymptomatic and self-limited infection in the general
population.19
The first known United States case of transfusion-transmitted
babesiosis (TTB) was described in 1979, and now >200 cases
have been identified.15 The incidence of TTB is estimated to be
1.1 cases per million of red blood cell units distributed.20 Most
cases of TTB occur when tick-acquired infection is greatest,
June to November. However, infection can occur at any time
because asymptomatic infection can last >1 year and the incuba-
tion period after a transfusion is generally 1 to 6 weeks but has
been documented up to 6 months.15-17 Transfusion-transmitted
babesiosis is not limited to endemic areas because of blood donor
travel and blood product transfer across geographic regions.
Most TTB is acquired through PRBCs; however, there have been
a few cases of TTB acquired from the small amount of residual
erythrocytes in platelet units.16
Post-solid organ transplant, Babesia infection is rare, and all
known cases have been related to transfusions that occurred in
the peri-transplant period.21 To date, there are no known cases
of Babesia transmitted via liver transplant documented in the
literature.
How Did This Patient Acquire Babesiosis?
The source of Babesia infection in this case was likely
transfusion related; however, it could have also been from
the transplanted liver or reactivation of a previous asympto-
matic infection. Before the patient developed fevers, she
had received 35 units of PRBCs, 1 unit of platelets, and 2
units of plasma (Figure 1). Infection from the transplanted
liver is unlikely given the lack of evidence of solid organ
transplant-transmitted infection in the literature. Further, if
the infection had been from an infected donor liver, a symp-
tomatic infection would have most likely occurred within
6 weeks posttransplant during the typical incubation time,
not 3 months posttransplant, given that the incubation time
is about 6 weeks.16 Because she became symptomatic
greater than 6 weeks into her hospitalization, a recently
acquired tick-borne infection in the patient herself was also
unlikely.
What Are Treatment Guidelines for Babesiosis?
Treatment of babesiosis depends on the severity of infection.22
Asymptomatic patients should not receive antimicrobial ther-
apy and should only be observed.10 Immunocompetent patients
with <4% parasitemia should be prescribed a 7- to 10-day
course of azithromycin and atovaquone.9,22 Patients with
>4% parasitemia should be hospitalized, receive antimicro-
bials, and are candidates for RBC exchange transfusion.10,23
Immunocompromised patients are at high risk of relapse.9,21 In
these patients, antimicrobial therapy should be prescribed for a
minimum of 6 weeks and continued 2 weeks past a negative
blood smear.10,23
What Is Apheresis and What Are Indications for It?
Therapeutic apheresis describes a procedure in which a centri-
fuge separates blood to remove one or more components from a
patient.24 Therapeutic plasma exchange is performed for many
patients with immune-mediated diseases including a spectrum
of infections, autoimmune disease, and hematology oncology
disorders.25 Removed plasma that is discarded and 5% albumin
or plasma products are used as replacement fluid.25
Erythrocytapheresis, or RBC exchange transfusion, is an
apheresis procedure in which patient erythrocytes are removed
and replaced with healthy donor PRBC units.24 In the United
States, the vast majority of RBC exchange transfusions are
performed in patients with sickle cell disease for primary or
secondary stroke prophylaxis.24 However, this procedure is
considered first-line therapy for patients with severe babesio-
sis.23,25 Cerebral malaria is sometimes treated with RBC
exchange; this diagnosis is quite rare in the United States.25
Table 3. Babesiosis and Malaria Comparison.
Babesiosis Malaria
Vector Ixodes scapularis tick10 Anopheles mosquito9
Endemic region Northeast and upper Midwest regions of the United
States.10,15
Tropical/subtropical areas, highest rates in parts of
Africa and the Oceania.9
Incubation Period Generally 1-6 weeks, but asymptomatic infection can
be >1 year.15-17
Generally 7-30 days, however, some subspecies
(Plasmodium vivax, Plasmodium ovale) can survive
dormant in the liver for prolonged periods.9
Clinical Presentation Fevers, chills, sweats, headache, body aches, loss of appetite, nausea or fatigue, dark urine, jaundice, altered
mental status, spleno/hepatomegaly and hepatic dysfunction.9,10
Fever Pattern Noncyclic.10 Cyclical or random.9
Blood smear morphology Small, pleomorphic intra- and extra-erythrocytic ring
forms; maltese cross tetrads are pathognomonic
for Babesia.9,11
Located only within erythrocytes and are
characterized by ring forms, schizonts and
gametocytes.9,11
Testing Blood smear, NAT, serology.9,11
Abbreviation: NAT, nucleic acid testing.
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How Does Apheresis Treat Babesiosis?
Red blood cell exchange transfusion in severe babesiosis can
prevent death from multi-organ dysfunction and is indicated if
parasitemia is >10%, hemoglobin is <10 g/dL, or if there is
evidence of pulmonary, liver, or renal impairment.25 In this
case, the patient met all criteria for exchange transfusion.
Exchange transfusion is effective treatment because it rapidly
decreases parasitemia, corrects anemia, and removes circulat-
ing toxic byproducts of cell lyses and inflammatory media-
tors.23,6 Response to treatment is achieved by tracking
parasitemia on peripheral smears.23
How Can TTB Be Prevented?
As demonstrated by this case, TTB can be severe and
life-threatening. Pathogen inactivation technology has been
Food and Drug Administration (FDA) approved for some types
of platelet units.26 This technology prevents replication of any
genetic material present in the bag, representing an agnostic
approach to eliminating transmission of any identified or uni-
dentified pathogen that may be present.26 However, the inacti-
vation technology cannot be used for PRBC units at this time,
leaving Babesia screening at the forefront of TTB prevention.27
Despite the ability to screen for the parasite, historically,
requirements only included asking blood donors if they ever
had babesiosis.28 Studies in endemic areas have shown that
NAT and serology testing significantly reduce TTB, with one
study estimating a reduction of 3.39 cases/100 000 PRBC
transfusions.29 However, this decrease comes at increased cost.
Endemic area screening costs on average US$760 000/quality
of life adjusted year.30 Despite the cost associated with testing,
prevention is paramount given the increased incidence and
severity of TTB.
In May 2019, the FDA published updated recommendations
regarding Babesia, with an intent to require blood collection
centers to be in compliance by May 2020.31 These recommen-
dations include year-round screening for Babesia with NAT for
all blood donors in 15 Babesia endemic states, unless pathogen
reduction is performed.31 Blood collection facilities outside of
Babesia endemic states are not required to test for the parasite
but must ask all donors if they have ever tested positive for
Babesia.31 All donors with a positive NAT must be deferred for
a minimum of 2 years after the last positive test.31
Teaching Points
 The safety of transfusions has improved greatly over
time; however, TTI persists as a transfusion risk.
Viruses, bacteria, protozoa, and prions can all cause
TTIs. Transfusion-transmitted viruses include the hepa-
titis viruses, HIV, CMV, parvovirus, and EBV.5 Babe-
siosis and malaria are protozoa transmitted infections
that very in incidence based on location.5 Incidence of
babesiosis ranges from 1/604 to 1/100 000 infections per
RBC unit transfused.6 Transfusion-transmitted malaria
is rare in the United States, occurring an estimated 0 to
0.18 cases per million units transfused or less.7
 TTI risk reduction can be achieved through careful donor
recruitment, questioning and testing, along with aseptic
phlebotomy technique. Despite a variety of test methodol-
ogies used for many TTIs, there no universal donor testing
in the United States for babesiosis and malaria.
 Babesiosis and malaria have similarities in presentation
and both should be in the differential of a patient with
fevers, hemolytic anemia, and history of transfusion.
These parasites can be differentiated by their life cycles
and morphology on peripheral blood smear.
 Microscopy-based identification is used to diagnosis
babesiosis and malaria. Thick blood smears, a drop of
blood on glass, establish the presence of parasites. Thin
blood smears, a drop of blood spread across a large
portion of a slide, are used to calculate percent parasi-
temia and examine morphology.11
 Babesiosis is an infectious disease caused by the proto-
zoan Babesia.10,15 Babesia species are endemic to the
Northeast and upper Midwest regions of the United
States and are transmitted by the I scapularis tick.10,15,16
Babesia sporozoites enter human erythrocytes where they
undergo asexual reproduction and cause erythrocyte
lyses.10 Immature forms include intra- and extracellular
ring-shaped trophozoites as well as Maltese-cross shaped
merozoites, all of which can be observed on blood
smear.9,10
 Malaria is an infectious disease caused by the protozoan
Plasmodium, transferred to humans by the Anopheles
mosquito vector.9 The parasite infects hepatocytes and
erythrocytes. Malaria fevers, depending on the subspe-
cies, can be cyclical or random and depend on RBC
rupture.5 In RBCs, the parasite forms trophozoites that
mature into schizonts and gametocytes.9 Schizonts are
unique to Malaria and can be found on blood smear.
Plasmodium ring forms, also observed on blood smear,
are strictly intracellular and have classic “headphone
morphology.”
 Therapeutic apheresis describes a procedure in which a
centrifuge separates blood to remove one or more com-
ponents from a patient.24 Therapeutic plasma exchange
is performed for a wide range of patients. Red blood cell
exchange transfusion in severe babesiosis can prevent
death from multi-organ dysfunction.
Declaration of Conflicting Interests
The author(s) declared the following potential conflicts of interest
with respect to the research, authorship, and/or publication of this
article: Dykes was a fourth year medical student at Sidney Kimmel
Medical College, Thomas Jefferson University when this case was
initially submitted, now she is an internal medicine intern at George-
town University. Peedin is an assistant professor in the department of




The author(s) disclosed receipt of the following financial support for
the research, authorship, and/or publication of this article: The article
processing fee for this article was funded by an Open Access Award
given by the Society of ‘67, which supports the mission of the Asso-
ciation of Pathology Chairs to produce the next generation of
outstanding investigators and educational scholars in the field
of pathology. This award helps to promote the publication of
high-quality original scholarship in Academic Pathology by authors
at an early stage of academic development.
ORCID iD
Kaitlyn C. Dykes https://orcid.org/0000-0002-1638-1755
Alexis R. Peedin https://orcid.org/0000-0003-3779-8602
References
1. Knollmann-Ritschel BEC, Regula DP, Borowitz MJ, Conran R,
Prystowsky MB. Pathology competencies for medical education
and educational cases. Acad Pathol. 2017:4. doi:10.1177/
2374289517715040
2. Choudhary NS, Saigal S, Bansal RK, Saraf N, Gautam D, Soin
AS. Acute and chronic rejection after liver transplantation: what a
clinician needs to know. J Clin Exp Hepatol. 2017;7:358-366. doi:
10.1016/j.jceh.2017.10.003
3. Bellone M, Hillyer CD. Acute hemolytic transfusion reactions. In:
Shaz BH, Hillyer CD, Roshal M, Abrams CS, eds. Transfusion
Medicine and Hemostasis: Clinical and Laboratory Aspects. 2nd
ed. Elsevier Science; 2013:401-408.
4. Josephson CD. Delayed hemolytic transfusion reactions. In: Shaz
BH, Hillyer CD, Roshal M, Abrams CS, eds. Transfusion Medi-
cine and Hemostasis: Clinical and Laboratory Aspects. 2nd ed.
Elsevier Science; 2013:409-412.
5. Katz LM, Dodd RY. Transfusion transmitted diseases. In: Shaz
BH, Hillyer CD, Roshal M, Abrams CS, eds. Transfusion Medi-
cine and Hemostasis: Clinical and Laboratory Aspects. 2nd ed.
Elsevier Science; 2013:453-466.
6. Spaete J, Patrozou E, Rich JD, Sweeney JD. Red cell exchange
transfusion for babesiosis in Rhode Island. J Clin Aphe. 2009;24:
97-105. doi:10.1002/jca.20197
7. Mungai M, Tegtmeier G, Chamberland M, Parise M. Transfusion-
transmitted malaria in the United States from 1963 through 1999.
N Engl J Med. 2001;344:1973-1978. doi:10.1056/NEJM2001
06283442603
8. Keeping blood transfusions safe: FDA’s multi-layered protections
for donated blood. U.S. Food and drug administration website.




9. Blevins SM, Greenfield RA, Bronze MS. Blood smear analysis in
babesiosis, ehrlichiosis, relapsing fever, malaria, and Chagas dis-
ease. Cleve Clin J Med. 2008;75:521-530.
10. Vannier E, Krause PJ. Human babesiosis. N Engl J Med. 2012;
366:2397-2407. doi:10.1056/NEJMra1202018
11. Rosenblatt JE. Laboratory diagnosis of infections due to blood
and tissue parasites. Clin Infect Dis. 2009;49:1103-1108. doi:10.
1086/605574
12. Persing DH, Mathiesen D, Marshall WF, et al. Detection of Babe-
sia microti by polymerase chain reaction. J Clin Microbiol. 1992;
30:2097-2103.
13. Villatoro T, Karp JK. Transfusion-transmitted babesiosis. Arch
Pathol Lab Med. 2018;143:130-134. doi:10.5858/arpa.2017-
0250-RS
14. Levin AE, Krause PJ. Transfusion-transmitted babesiosis: is it
time to screen the blood supply? Curr Opin Hematol. 2016;23:
573-580. doi:10.1097/MOH.0000000000000287
15. Centers for Disease Control and Prevention (CDC). Babesiosis
surveillance – 18 states, 2011. MMWR Morb Mortal Wkly Rep.
2012;61:505-509. doi:mm6127a2
16. Herwaldt BL, Linden JV, Bosserman E, Young C, Olkowska D,
Wilson M. Transfusion-associated babesiosis in the United States:
a description of cases. Ann Intern Med. 2011;155:509-519. doi:
10.7326/0003-4819-155-8-201110180-00362
17. Lux JZ, Weiss D, Linden JV, et al. Transfusion-associated babe-
siosis after heart transplant. Emerg Infect Dis. 2003;9:116-119.
doi:10.3201/eid0901.020149
18. Joseph JT, Roy SS, Shams N, et al. Babesiosis in lower Hudson
Valley, New York, USA. Emerg Infect Dis. 2011;17:843-847.
doi:10.3201/eid1705.101334
19. Bloch EM, Levin AE, Williamson PC, et al. A prospective evalua-
tion of chronic Babesia microti infection in Serore active blood
donors. Transfusion. 2016;56:1875-1882. doi:10.1111/trf.13617
20. Tonnetti L, Eder AF, Dy B, et al. Transfusion-transmitted Babesia
microti identified through hemovigilance. Transfusion. 2009;49:
2557-2563. doi:10.1111/j.1537-2995.2009.02317.x
21. Brennan MB, Herwaldt BL, Kazmierczak JJ, et al. Transmission
of Babesia microti parasites by solid organ transplantation. Emerg
Infect Dis. 2016;22:1869-1876. doi:10.3201/eid2211.151028
22. Parasites-babesiosis: Resources for health professionals. Centers
for disease control and prevention website. Updated October 30,
2019. Accessed August 14, 2020. https://www.cdc.gov/parasites/
babesiosis/health_professionals/index.html#tx
23. Sanchez E, Vannier E, Wormser GP, Hu LT. Diagnosis, treat-
ment, and prevention of Lyme disease, human granulocytic ana-
plasmosis, and babesiosis: a review. JAMA. 2016;315:1767-1777.
doi:10.1001/jama.2016.2884
24. Pham HP, Schwartz J. Overview of therapeutic apheresis. In:
Shaz BH, Hillyer CD, Roshal M, Abrams CS, eds. Transfusion
Medicine and Hemostasis: Clinical and Laboratory Aspects. 2nd
ed. Elsevier Science; 2013:467-480.
25. Schwartz J, Padmanabhan A, Aqui N, et al. Guidelines on the use
of therapeutic apheresis in clinical practice-evidence-based
approach from the writing committee of the American Society
for Apheresis: the seventh special issue. J Clin Apher. 2016;31:
149-162. doi:10.1002/jca.21470
26. Irsch J, Lin L. Pathogen inactivation of platelet and plasma blood
components for transfusion using the INTERCEPT blood system.
Transfus Med Hemother. 2011;38:19-31. doi:10.1159/000323937
27. Drew VJ, Barro L, Seghatchian J, Burnouf T. Towards pathogen
inactivation of red blood cells and whole blood targeting viral
Dykes and Peedin 9
DNA/RNA: design, technologies, and future prospects for devel-
oping countries. Blood Transfus. 2017;15:512-521. doi:10.2450/
2017.0344-16
28. US Department of Health and Human Services Food and
Drug Administration Center for Biologics Evaluation and
Research. Recommendations for reducing the risk of
transfusion-transmitted babesiosis: draft guidance for indus-
try. 2001 D-0220. Published October 18, 2006. Updated July
2018. Accessed April 8, 2019. https://www.fda.gov/media/
114847/download
29. Moritz ED, Winton CS, Johnson ST, et al. Investigational screen-
ing for Babesia microti in a large repository of blood donor
samples from nonendemic and endemic areas of the United States.
Transfusion. 2014;54:2226-2236. doi:10.1111/trf.12693
30. Simon MS, Leff JA, Pandya A, et al. Cost-effectiveness of blood
donor screening for Babesia microti in endemic regions of the
United States. Transfusion. 2014;54:889-899. doi:10.1111/trf.
12492
31. US Department of Health and Human Services Food and Drug
Administration Center for Biologics Evaluation and Research.
Recommendations for reducing the risk of transfusion-
transmitted babesiosis: guidance for industry. FDA-2018-D-
2478. Published May 20, 2019. Accessed August 14, 2020.
https://www.fda.gov/media/114847/download
10 Academic Pathology
